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Introduction: The emergence of multiple myeloma as a second malignancy in patients with essential
thrombocythemia is extremely rare. Several cases have been published so far, pointing out the impact of a
cytotoxic effect during treatment of essential thrombocythemia on the development of multiple myeloma.
Case presentation: We report the case of a 52-year-old Caucasian man who presented to our hospital because of
leukocytosis, a slightly decreased hemoglobin level and thrombocytosis. After a complete hematological work-up,
essential thrombocythemia was diagnosed. The patient was included in a multicenter clinical study, treated with
anagrelide and his platelet counts were maintained in the normal range for more than 3 years. A sudden drop in
his hemoglobin level with normal leukocyte and platelet count occurred at the same time as a back pain. Magnetic
resonance imaging of his spine revealed the existence of a pathological fracture of Th4, the collapse of the upper
edge of Th7 and osteolytic lesions of multiple thoracic vertebrae. Repeated hematological examinations, including
bone biopsy with immunohistochemistry, disclosed diagnosis of multiple myeloma of the non-secretory type.
Conclusions: To the best of our knowledge this is the first published case in which multiple myeloma developed
during the treatment of essential thrombocythemia with the non-cytotoxic drug anagrelide. Our attempts to find a
common origin for the coexistence of multiple myeloma and essential thrombocythemia have not confirmed the
genetic basis of their appearance. Further studies are needed to determine the biological impact of this
coexistence.
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It is well known that essential thrombocythemia (ET)
can progress to myelofibrosis or acute leukemia [1]. The
occurrence of other secondary hematologic malignancies
in patients with ET includes non-Hodgkin's lymphoma
and myelodysplastic syndrome but development of multiple
myeloma (MM) is extremely rare [2,3]. Several cases
have been published so far, pointing out the impact of
toxic effects during treatment of ET on the development
of MM [4-6].* Correspondence: danijela.lekovic@yahoo.com
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reproduction in any medium, provided the orWe report the case of a patient with ET who was
treated with non-cytotoxic therapy anagrelide, in whom
MM appeared almost 4 years after the diagnosis of ET. The
expression of the angiogenic factors, vascular endothelial
growth factor (VEGF), endothelial nitric oxide synthase
(eNOS) and hypoxia-inducible factor 1-alpha (HIF1α),
was analyzed in the bone marrow (BM) biopsy samples of
our patient.Case presentation
A 52-year-old Caucasian man was referred to our clinic
with leukocytosis, slightly decreased hemoglobin (Hb)
level and thrombocytosis. He had dizziness in the last
months. There was a history of 20 years of smoking and no
exposure to any cytotoxic agents. His physical examinationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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white blood cells (WBC)=14.1×109/L with normal cell
differentiation (61% of neutrophils, 7% of monocytes, 28%
of lymphocytes, 3% of eosinophils and 1% of basophiles),
Hb=135g/L, mean corpuscular volume 88fL, normal re-
ticulocyte count and platelets (Plt)=1130×109/L. Serum
iron (9.6μmol/L, total iron-binding capacity=55.5μmol/L)
and protein (serum total protein 77g/L, albumin 46g/L)
analyses were normal. A chest X-ray, an ultrasound of
his abdomen and an echocardiogram were normal. BM
aspiration showed mainly sheets of megakaryocytes with
normal marrow iron stores. A BM biopsy revealed mega-
karyocytic hyperplasia without signs of fibrosis, and large
megakaryocytes with hyperlobated nuclei and a tendency
to group in clusters (Figure 1a). Conventional cytogenetic
testing showed a normal male karyotype 46,XY (Figure 2).
Mutation of JAK2V617F was not detected in granulocytes
of peripheral blood.Figure 1 Histological and immunohistochemical analysis of essent
marrow biopsy specimen when essential thrombocythemia was diagn
multiple myeloma (MM) was diagnosed showing the diffuse infiltration
specimen when MM was diagnosed showing the kappa positive plasm
diagnosed showing the CD138 positive plasma cells (×200). (e) Bone m
diffuse infiltration with plasma cells (Giemsa, ×200). (f) Bone marrow b
positive plasma cells (×200).Based on these findings, the diagnosis of myeloprolifera-
tive neoplasm (MPN)-ET was made. The thromboreductive
therapy with anagrelide within the multicenter clinical
study was started when his Plt count was 1309×109/L. The
patient was treated for more than 3 years with a daily dose
of 1mg. A complete hematological response was achieved
after 1 month of treatment and thereafter Plt counts were
maintained in normal values (from 176 to 423×109/L)
without any thrombotic or hemorrhagic complications.
However, 3.5 years after ET diagnosis during a routine
checkup, a drop in Hb level was observed (94g/L)
with normal WBC (5.8×109/L), and Plt (276×109/L).
Thromboreductive therapy was discontinued. Soon, the pa-
tient started to complain of persistent back pain. Magnetic
resonance imaging of his spine revealed the pathological
fracture of Th4, collapse of the upper limb of Th7 and
multiple focal osteolytic lesions of thoracic vertebrae. A
standard radiography showed multiple osteolytic lesionsial thrombocythemia and multiple myeloma. (a) Initial bone
osed (Giemsa, ×200). (b) Bone marrow biopsy specimen when
with plasma cells (Giemsa, ×200). (c) Bone marrow biopsy
a cells (×200). (d) Bone marrow biopsy specimen when MM was
arrow biopsy specimen after MM chemotherapy showing the
iopsy specimen after MM chemotherapy showing the CD138
Figure 2 Karyogram from a bone marrow metaphase of the patient showing 46,XY.
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of his left ischium, left proximal part of the radius and
on the upper third of both femurs. In a CBC, a further
decrease in his Hb level and Plt was observed (Hb=75g/L,
Plt=33×109/L). His erythrocyte sedimentation rate was
115mm/hour, C-reactive protein=12.8mg/L, urea=14mmol/L,
creatinine=181μmol/L, calcium=3.5mmol/L, iron=46.6μmol/
L, ferritin=1100ug/L, β-2 microglobulin=6.21mg/L and
lactate dehydrogenase=1034U/L. His total serum protein
(68g/L) and albumin (40g/L) were normal. His total urine
protein level was 0.59g/L. His serum immunoglobulins (Ig)
were slightly decreased: IgG=5.15g/L, IgA=0.64g/L, and
IgM=0.19g/L. Immunofixation did not reveal any monoclo-
nal protein in his serum and urine. Immunohistochemistry
(IHC) of the BM biopsy revealed infiltration with 80% of
monoclonal plasma cells (Figure 1b–d): LCA-, EMA-, Pax5,
CD20+/−, CD3-, CD43-, CD38+, CD138+, kappa+, lambda-,
IgG+, IgA-, IgM-, IgD-, CD31-, CD56-, Cyclin D1-, MUM1+,
CD10-, and EBV-. Ki67+ was expressed in 20% of tumor
cells (Figure 1c–f ). Flow cytometry of the BM aspiration
showed 8% of monoclonal plasma cells: CD38+high,
CD138+high, CD117+high, cyVS38c+hetero, CD20+hetero,
smIgKappa+hetero, cyIgKappa+hetero, CD19-, cCD79a-,
CD45-, CD56-, CD52-, and CD10- (Figure 3a–f). According
to the above, the diagnosis of non-secretory MM, clin-
ical stage IIIB (Durie–Salmon) was made, with the
International Staging System – Stage 3. The patient was
treated with cyclophosphamide, thalidomide, and dexa-
methasone (CTD) chemotherapy every 3 weeks (cyclo-
phosphamide 500mg/kg/day D1, D8, D15; thalidomide
100mg/day every day; dexamethasone 40mg/day D1–4,
D12–15). Zoledronic acid was administrated intravenously
in doses of 4mg monthly for 6 months. Radiotherapy was
applied on to Th4 for the pathological fracture and per-
sistent back pain. After six courses of CTD, despite a very
good performance status, the radiography revealed the
presence of multiple osteolytic lesions and pathological
fracture of Th4 and Th5. A BM biopsy with IHC showed
persistent infiltration with 90% of monoclonal plasma
cells. The patient continued treatment with vincristine,doxorubicin, and dexamethasone chemotherapy (vincristine
0.4mg/day D1–4; Adriamycin® (doxorubicin) 9mg/m
2/day
D1–4; dexamethasone 40mg/day D1–4, D9–12, D17–20) every
4 weeks, and received six courses without response. During
palliative treatment with thalidomide 200mg/day, the
patient died 22 months from MM diagnosis.
Additional analyses were performed including interphase
fluorescence in situ hybridization (FISH) on two paraffin-
embedded BM biopsy specimens: the first specimen was
from the MM diagnosis and the second from the ET
diagnosis. FISH analyses for the t(4;14), t(14;16), del(17)
and del(13) were done with Abbott-Vysis probes. In both
paraffin specimens, a normal signal pattern was found in
all analyzed nuclei (at least 100) for each applied FISH
probe (Figure 4).
The expression of angiogenic factors VEGF, eNOS and
HIF1α was analyzed using IHC on BM biopsy specimens
(Table 1). Immunoreactive complex was visualized with
DAKO Liquid DAB+ Substrate-Chromogen System coun-
terstained with Mayer's hematoxylin and evaluated under a
light microscope. The results of the expression of angio-
genic factors were obtained counting the number of
positively stained endothelial cells using the hot spot
method (Figure 5). Normal values of analyzed angiogenic
factors were found at the time of ET diagnosis. However,
VEGF and active nuclear form of HIF-1α were elevated at
the time of MM diagnosis and all angiogenic factors were
more than twice elevated after MM treatment.
Discussion
ET is a MPN, characterized by the clonal proliferation of
megakaryocytes in the BM and high Plt levels in periph-
eral blood [2]. By contrast, MM is a plasma cell neoplasm
of post-germinal center, long-living plasma cells, in which
the Ig genes have undergone a class switch with somatic
hypermutation [7]. The non-secretory MM is a rare
variant (1 to 5%) of the disease which is characterized by
the clonal proliferation of the plasma cells in BM without
detectable monoclonal protein in the serum or urine by
conventional techniques [8]. The diagnosis often rests on
Figure 3 Immunophenotypic profile of bone marrow multiple myeloma cells determined by flow cytometry. a) CD45-, b) CD38+high,
CD138+high, c) CD117+high, d) CD20+hetero, e) cyIgKappa+hetero, cVS38+hetero, f) CD56- presented on biparametric histograms.
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in the marrow as well as on the presence of lytic bone
lesions, which are common in these patients. Myeloma
plasma cells of the presented patient have shown typical
immunophenotypic characteristics, detected by flow cytom-
etry, but with two unusual findings: the first, concomitant
expression of surface and cytoplasmatic form of the kappa
light chain and CD20. These features are characteristics of
early plasma cells and plasmablasts. The second unusual
finding was the aberrant expression of CD117 and CD20
without the expression of the CD56 molecule. It wasFigure 4 Interphase fluorescence in situ hybridization analysis on par
myeloma and essential thrombocythemia. Plasma cells nuclei negative
MAF probe, (c) del(13q14.3)-D13S319 probe, (d) del(17p13.1)- TP53 probe.
probe, (f) t(14;16)(q32;q23)- IGH/MAF probe, (g) del(13q14.3)-D13S319 probalready observed that MM without CD56 expression
might be associated with more aggressive disease and
extramedullary dissemination [9].
According to previous reports, ET preceded MM in eight
cases and both diseases were diagnosed simultaneously
at their onset in three cases. MM had never preceded
ET [4-6]. There is a report about a patient with ET who
received busulphan plus hydroxyurea and then developed
plasma cell leukemia [10].
The association of MM and ET is still unclear. Previous
literature emphasizes the impact of cytotoxic effects in ETaffin-embedded bone marrow tissue at diagnosis of multiple
for: (a) t(4;14)(p16;q32)- IGH/FGFR3 probe, (b) t(14;16)(q32;q23)- IGH/
Megakaryocytes nuclei negative for (e) t(4;14)(p16;q32)- IGH/FGFR3
e, (h) del(17p13.1)- TP53 probe.
Table 1 Percentage of vascular endothelial growth factor, endothelial nitric oxide synthase and hypoxia-inducible
factor 1-alpha positive cells in essential thrombocythemia and multiple myeloma (before and after chemotherapy) on







Control 8 8.19 9.84 / 4.05
Essential thrombocythemia 7.39 8.08 8.15 / 0
Multiple myeloma 20.41 5.08 1.91 / 8.18
Multiple myeloma+chemotherapy 22.68 21.94 6.3 / 9.91
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malignancies [4-6]. One study based on the follow-up of
114 patients with ET, reported a higher incidence of
second malignancies (leukemias, chronic lymphocytic
leukemia and solid tumors) in hydroxyurea-treated pa-
tients (3.9%). Moreover, the significantly increased rate of
second malignancies was found in a cohort of patients
with ET sequentially treated with busulphan and hydroxy-
urea [11]. One of the largest studies, which involved the
long-term follow-up of 331 patients with ET, observed
second hematological malignancies in 15 patients (4.5%),
including acute myeloid leukemia, acute lymphoblasticFigure 5 Expression of vascular endothelial growth factor (VEGF), endo
1-alpha (HIF1α) was analyzed using immunohistochemistry on bone ma
multiple myeloma (MM) (before and after chemotherapy). VEGF expressi
chemotherapy. eNOS expression: (d) at ET diagnosis, (e) at MM diagnosis, (f)
MM diagnosis, (i) in MM after chemotherapy. Magnification x40. Immunoreacleukemia, non-Hodgkin lymphoma (follicular lymphoma
and diffuse large B-cell lymphoma) and small lymphocytic
lymphoma [3]. According to the type of ET treatment,
second malignancies were documented in 7.3% of patients
who did not receive any treatment, in 11.2% of those
treated only with hydroxyurea, in 26.3% of those who
received only alkylating agents, and in 25% of those
treated with alkylating agents followed by hydroxyurea
[3]. Considering the above findings, the occurrence of
MM was not remarked upon during follow-up of patients
with ET, indicating the sporadic coexistence of these two
diseases.thelial nitric oxide synthase (eNOS) and hypoxia-inducible factor
rrow biopsy specimens of essential thrombocythemia (ET) and
on: (a) at ET diagnosis, (b) at MM diagnosis, (c) in MM after
in MM after chemotherapy. HIF1α expression: (g) at ET diagnosis, (h) at
tive cells are colored brown. The black arrows point toward positive cells.
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among the 383 patients with MM, only this one was
found to have MM in coexistence with ET. Concerning
the treatment, our patient is unique because he was treated
for ET with anagrelide, a non-cytotoxic therapy. Anagrelide
is an efficient Plt-lowering agent in most patients with ET,
including patients being treated for the first time and
in those refractory to other thromboreductive therapy.
Anagrelide exerts its effect by reducing the differentiation
at the late stage of megakaryocytic development, which
leads to reduced Plt production [12]. It has been observed
in long-term follow-up that anagrelide-treated patients with
ET did not develop acute leukemia or other hematological
malignancies [12-14].
There are suggestions that MM clones have a higher
proliferative potential compared with ET clones [5]. Never-
theless, the cytotoxic effect of anti-myeloma therapy on
ET cannot be excluded. Previous publications have shown
that angiogenesis could play an important role in the
biology of hematological malignancies, including ET and
MM. VEGF, a major angiogenic factor, was identified
in higher concentrations in untreated patients with ET.
However, in anagrelide-treated patients with ET, elevated
VEGF and increased density of blood vessels were not
observed [15,16]. By contrast, an increased level of
angiogenesis is a regular characteristic of MM and has a
prognostic value [17]. In our case, angiogenic factors were
within normal ranges at the time of ET diagnosis. After the
occurrence of MM, angiogenic factors increased despite
treatment with the angiogenic drug thalidomide; that
finding correlated with clinical resistance and continuous
disease progression.
Conclusions
To the best of our knowledge, this is the first published
case in which MM developed during the treatment of
ET with the non-cytotoxic drug anagrelide. Our attempts
to find a common origin for the coexistence of MM and
ET have not confirmed the genetic basis of their appear-
ance. Further studies are needed to determine the biological
impact of this coexistence.
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